Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
about
The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosomeRecombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.Progress in the development of human parainfluenza virus vaccinesAttenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and ChildrenRespiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.Recent developments with live-attenuated recombinant paramyxovirus vaccines.A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region.Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.Progress in respiratory virus vaccine development
P2860
Q27311445-4E01D652-61F8-4B94-978B-94DBBD0AF90BQ34101229-971B70BE-F5E3-450F-813C-E650EE9F2F7EQ34209872-6803E404-BFDC-448D-8513-43F7A584EADDQ36086315-FA2834AA-373B-43B0-8C35-6430E86B815EQ36377405-BF492E5D-40EC-40BE-8E2E-FD3451A5873AQ36607430-0D56171C-683B-4B50-9E9A-4266F83CFD35Q36845674-E5D564C4-B7F6-4230-AA0F-E87349474487Q36898701-5F6A1E47-E4A7-4964-B059-767187F65775Q37468212-43EA207E-6094-4F4C-AE4B-23D1A31BCA3AQ38008607-D158D9BC-CDD8-4DE2-91F0-45807D062FCFQ38960717-A3066CF4-0F89-4A4D-9C45-7F9C1635FDC7Q40067156-3A0BE96B-C6C4-4B53-A706-F823EC3C39C2Q40072947-11EEC8DD-875C-483B-B44D-1027269109C7Q56894869-58EFA66C-28EC-4E1B-B8E3-31AB5EFC5FDA
P2860
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@ast
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@en
type
label
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@ast
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@en
prefLabel
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@ast
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@en
P2093
P2860
P356
P1433
P1476
Attenuation and efficacy of hu ...... ations in the P/C and L genes.
@en
P2093
Adam Castaño
Brian R Murphy
Emmalene J Bartlett
Mario H Skiadopoulos
Peter L Collins
Sonja R Surman
P2860
P356
10.1186/1743-422X-4-67
P577
2007-07-02T00:00:00Z